Ciba launches Vivelle estradiol transdermal patch in four dosage strengths.
Executive Summary
CIBA VIVELLE ESTROGEN PATCHES LAUNCHED MARCH 25 IN FOUR DOSAGE STRENGTHS to allow physicians to prescribe patients the lowest possible dose of estrogen replacement therapy. The 17-beta estradiol transdermal patch, licensed from Miami-based Noven for treatment of moderate to severe vasomotor menopausal symptoms, is available in .0375 mg, .05 mg, .075 mg and .1 mg daily doses.